Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival

CNBC April 9, 2024
Annika Kim Constantino, Ashley Capoot

Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday.

But J&J’s drug is walking away with a notable edge over its rival.

The FDA expanded the approvals of both therapies, allowing patients to use them as earlier lines of treatment for a type of blood cancer called multiple myeloma. That can damage the bones, immune system, kidneys and red blood cell count.

Before that decision, J&J’s drug Carvykti and Bristol Myers’s treatment Abecma were both only available to people who previously received at least four specific drug regimens for the incurable blood cancer.

First and foremost, the expanded approvals are a...

Today's Sponsors

Today's Sponsor